Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Migraine Phase Dietary Supplement Addon

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07634146Not ApplicableNot Yet Recruiting

Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study

NCT00904098Phase 4CompletedPrimary

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

Showing all 2 trials

Research Network

Common Treatments

  • Migraine Phase Dietary Supplement Addon1
  • Reference Dietary Supplement1
  • Usual Care1
  • Luteal Phase Dietary Supplement Addon1
  • Foundational Dietary Supplement1

Active Sponsors

  • Miracle Wellness LLC1
  • Endo USA Inc., a Keenova Therapeutics Company1

Top Investigators

Related Conditions

  • Migraine1
  • Migraine In Adults1
  • Migraine Headache1
  • Menstrual Migraine1
  • Migraine Disability1

Activity Timeline